Table 1. Comparison of treatment response of biologic agents and small molecules in psoriasis and psoriatic arthritis.
| Agent | Psoriasis | Psoriatic Arthritis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | N | PASI 75/pbo (%) | Study | N | ACR 20/pbo (%) | D/E +/- | Axial +/- | X-ray +/- | |
| Secukinumab | Juncture | 676 | 87/3.3 | Future 2 | 397 | 54/7 | - | ND | ND* |
| Ixekizumab | Uncover 2 | 1224 | 90/48 | RHAP | 417 | 60/31 | +/- | ND | + |
| Brodalumab | Amagine 2 | 1831 | 86/8 | Phase II | 168 | 39/18 | - | - | - |
| Tildrakizumab | Phase IIb | 355 | 74/4 | ND | ND | ND | ND | ND | ND |
| Guselkumab | Phase II | 293 | 81/5 | ND | ND | ND | ND | ND | ND |
| Apremilast | Esteem 1 | 844 | 33/5 | PALACE 1 | 504 | 31/19 | - | - | - |
Results from phase II and phase III studies in psoriasis and PsA are enumerated in the table. The data are derived from the trials and should not be used to compare agents since the study populations differ. The results for the most responsive cohorts are shown. Abbreviations: pbo-placebo; PASI Psoriasis Activity Skin Index ;(D/E)- Dactylitis/Enthesitis, only significant changes listed as +; (ACR)American College of Rheumatology 20 response; Axial-response of axial disease to treatment; documented improvement in pre-defined radiographic endpoints (X-ray).
*
Inhibition of radiographic damage was presented in the FUTURE2 trial [15].